INVESTIGADORES
VALDOMERO Analia
artículos
Título:
Assessment of Potential Thrombogenicity in an Animal Model of a Triple Viral Inactivated Factor IX Concentrate Manufactured in Argentina
Autor/es:
MARTINEZ MC; RODRIGUEZ R; MARINSALDI A; RODRIGUEZ GR; GUGLIELMONE HA; BERNARDI ME; VALDOMERO A; CUADRA GR
Revista:
Annals of hematology and oncology
Editorial:
Austin Publishing Group
Referencias:
Año: 2021 vol. 8 p. 1 - 3
ISSN:
2375-7965
Resumen:
The risk of thromboembolism with FIX replacement therapy remains a concern for hemophilic B patients. Previous studies from our laboratory demonstrated that the activated factor content of the FIX Plasma Derived (FIXpd) manufactured at UNC-Hemoderivados was negligible by in vitro assay. Despite this, we considered it important to conduct studies to assess the potential thrombogenic risk of our FIXpd concentrates using a modified stasis animal model. FIXpd were inject doses of 100 or 200 IU F IX kg-1 and some samples were supplemented with heparin (
